US EditionNovo Nordisk's obesity drug falls short against Eli Lilly's in trial
CagriSema showed 20.2% weight loss at 84 weeks versus tirzepatide's 23.6%, causing a 13% share drop and a new 52-week low for Novo Nordisk, data showed.
- On Monday, Novo Nordisk A/S shares plunged and hit a 52-week low after REDEFINE 4 failed to meet the primary non-inferiority endpoint for weight loss versus tirzepatide at 84 weeks.
- The 84-week REDEFINE 4 trial showed 809 subjects compared once-weekly CagriSema 2.4/2.4 mg with tirzepatide 15 mg, reporting weight loss of 20.2% vs 23.6% and 23% vs 25.5% favoring tirzepatide.
- CagriSema showed a generally safe profile, with most gastrointestinal adverse events mild to moderate and diminishing over time, while investors expressed concern over its uphill launch, Markus Manns, Union Investment said.
- Novo Nordisk says it will keep testing higher doses and combinations, expects FDA decision late 2026, and faces a setback as shares fell nearly 50% last year.
- Novo Nordisk plans a higher-dose CagriSema trial initiation in the second half of 2026 and expects the REDEFINE 11 readout in the first half of 2027, Martin Holst Lange said.
39 Articles
39 Articles
Novo Nordisk battles ‘obsolete’ accusations over new weight loss drug
Investors called on Novo Nordisk to pivot to sectors beyond weight loss after disappointing trial results for a new drug saw the Danish pharmaceutical giant’s stock plummet. The Ozempic maker established the modern market for GLP-1 weight loss drugs, but its next-generation treatment, CagriSema, underperformed compared to a similar offering from US-based Eli Lilly. One Deutsche Bank analyst called Novo’s new drug “obsolete,” a characterization t…
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
Novo Nordisk (NYSE:NVO), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its next-generation obesity drug, had not fared well in a head-to-head trial. Trading volume reached 94.9 million shares, about 343% above its three-month average of 21.4 million shares. Novo Nordisk IPO'd in 1981 and has grown 24,669% since going public.How the …
Jyllands-Posten
avisendanmark.dkNew data about pharmaceutical giant Novo Nordisk's weight loss hope Cagrisema has apparently not gone down well with investors. Late Monday afternoon at the close of trading, the pharmaceutical company's B-share closed at ...
The Danish pharmaceutical company Novo Nordisk is sinking more than 14% this Monday after publishing a study between its slimming compound CagriSema and the tirzepatide of its rival Eli Lilly which has produced a comparatively unfavourable result for the first molecule. Thus, the quotation of Novo Nordisk plummeted 14.53% in the Cupenhage stock exchange in the equator of the session, up to 257.3 Danish kroner (34.44 euros). According to the pres…
A damper for the Danish pharmaceutical giant Novo Nordisk: The latest study on the hope carrier Cagrisema clearly misses expectations. Investors react shocked. Laughing third is Eli Lilly.
Novo Nordisk's New Obesity Drug Fails a Big Test
Novo Nordisk just learned its latest much-hyped obesity drug may not actually live up to the hype. Shares of the Danish pharma giant plunged 16% Monday after it reported that its experimental drug, CagriSema, did not match the weight loss achieved by Eli Lilly's rival drug in a direct comparison...
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
